Debt reduced
Total debt is down from ₹3,877 to ₹0 over 7 years (100.0% lower); debt-to-equity moved 0.69× → 0.00×.
Importance 67 / 95 · financial health
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Total debt is down from ₹3,877 to ₹0 over 7 years (100.0% lower); debt-to-equity moved 0.69× → 0.00×.
Importance 67 / 95 · financial health
Over 5 years the stock returned 40.6% a year while profit compounded at 7.0% a year.
Importance 63 / 95 · business vs stock
Profit has swung sharply over 7 years (from ₹-1,434 to ₹1,362) — one year is a weak guide to the earnings power.
Importance 62 / 95 · growth
EBITDA margin of 29.6% is the widest in 7 years (prior range 17.2% to 20.2%).
Importance 62 / 95 · profitability
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 4.3% a year over 7 years, from ₹6,305 cr in FY2019 to ₹8,440 cr in FY2026. Net profit was a loss of ₹201 cr in FY2026, including a one-off charge of ₹1,801 cr; excluding it, a profit of about ₹1,600 cr.
Profit has swung sharply over 7 years (from ₹-1,434 to ₹1,362) — one year is a weak guide to the earnings power.
Rule EARNINGS_VOLATILE
Reported net profit grew 30.1% (FY2025 → FY2026), but pre-tax profit was ₹1,985 — a large exceptional item this year accounts for most of the gain, so the underlying trend is softer than the headline.
Revenue grew 27.5% year on year (FY2025 → FY2026).
Revenue has compounded at 8.1% a year over 7 years (₹9,865 → ₹16,983) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,157 cr (down 31.3% on the same quarter last year) and net profit ₹264 cr (down 56.8%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹264 cr, down 56.8% from ₹610 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 revenue was ₹4,157 cr, down 31.3% from ₹6,047 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit declined 56.8% vs the same quarter last year, reversing the growth seen in the two preceding quarters (+6773.2% and +927.9%).
Rule QTR_TREND_REVERSAL
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 3,388 | +35.1% | 348 | −205.2% | 10.3% |
| Q4 FY25 | 3,256 | +6.3% | 4 | −100.4% | 0.1% |
| Q1 FY26 | 3,264 | +0.6% | 47 | −86.2% | 1.4% |
| Q2 FY26 | 6,047 | +76.1% | 610 | +72.2% | 10.1% |
| Q3 FY26 | 3,901 | +15.1% | 403 | +15.9% | 10.3% |
| Q4 FY26 | 3,771 | +15.8% | 301 | +6773.2% | 8.0% |
| Q1 FY27 | 4,018 | +23.1% | 483 | +927.9% | 12.0% |
| Q2 FY27 | 4,157 | −31.3% | 264 | −56.8% | 6.3% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 21.9% in FY2026, against 28.6% in FY2019. ROE was -0.8% and ROCE 6.5% in FY2026.
EBITDA margin of 29.6% is the widest in 7 years (prior range 17.2% to 20.2%).
Rule MARGIN_AT_MULTI_YEAR_HIGH
EBITDA margin improved from 18.5% to 29.6% of revenue.
ROE rose from 12.5% to 14.1%, but reported profit this year was lifted by a large exceptional item this year (pre-tax profit was ₹1,985) — the operating return moved less than this.
It had little or no debt in FY2026 (debt-to-equity 0.00x). Operating cash flow was 0.37x net profit.
Total debt is down from ₹3,877 to ₹0 over 7 years (100.0% lower); debt-to-equity moved 0.69× → 0.00×.
Rule DEBT_FELL_MULTIYEAR
Operating cash flow has matched or exceeded reported profit in 4 of the last 5 profit-making years (latest 2.53×).
Debt-to-equity fell from 0.25× to 0.00× year on year.
Within its 12-company Pharmaceuticals peer group, it ranks 7 of 12 on return on equity and 6 of 12 on EBITDA margin. P/E is not meaningful this year because FY2026 profit is driven by a one-off charge.
Ranked against 12 pharmaceuticals (FY2026, consolidated). No peer-relative rule fired for this company.
GLENMARK · 1st of 12 · set median 14.8%
GLENMARK · 6th of 12 · set median 28.7%
GLENMARK · 7th of 12 · set median 14.4%
GLENMARK · 8th of 12 · set median 45.3×
On the trailing twelve months. Last full year: P/E 54.9× · P/S 4.3× · ROE 14.1%. TTM and full-year EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 41.0% over 1 year, up 241% over 3 years (50.4% a year) and up 449% over 5 years (40.6% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 1.2% below its 52-week high.
Over 5 years the stock returned 40.6% a year while profit compounded at 7.0% a year.
Rule STOCK_RAN_AHEAD
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,305 | 6,713 | 7,568 | 8,142 | 8,221 | 7,891 | 9,226 | 8,440 |
| Total income | 6,780 | 7,319 | 7,964 | 8,756 | 9,207 | 9,059 | 9,583 | 9,212 |
| EBITDA | 1,803 | 1,911 | 2,287 | 2,303 | 2,459 | 2,410 | 2,601 | 1,849 |
| Profit before tax | 1,818 | 1,535 | 1,944 | 2,337 | 1,572 | 7,001 | 2,154 | −266 |
| Net profit | 1,622 | 1,355 | 1,649 | 1,998 | 1,209 | 5,167 | 1,610 | −201 |
| EPS (₹) | 57.5 | 48.0 | 58.5 | 70.8 | 42.8 | 183.1 | 57.1 | −7.1 |
| Net worth | 11,942 | 13,226 | 14,810 | 16,739 | 17,877 | 22,971 | 24,504 | 24,150 |
| Total debt | 3,134 | 3,574 | 3,626 | 3,670 | 3,156 | 657 | 699 | 0 |
| Operating cash flow | — | — | 1,243 | 1,216 | 1,474 | −495 | 589 | 543 |
| Free cash flow | — | — | 1,032 | 1,053 | 1,601 | −690 | 249 | 266 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 6.5 | 12.7 | 7.6 | 1.0 | -4.0 | 16.9 | -8.5 |
| Profit growth YoY | — | -16.5 | 21.8 | 21.1 | -39.5 | 327.5 | -68.8 | -112.5 |
| Profitability | ||||||||
| EBITDA margin % | 28.6 | 28.5 | 30.2 | 28.3 | 29.9 | 30.5 | 28.2 | 21.9 |
| Net margin % | 23.9 | 18.5 | 20.7 | 22.8 | 13.1 | 57.0 | 16.8 | -2.2 |
| Return on equity % | 13.6 | 10.8 | 11.8 | 12.7 | 7.0 | 25.3 | 6.8 | -0.8 |
| Return on capital % | 11.3 | 11.1 | 12.1 | 11.0 | 11.0 | 9.9 | 9.8 | 6.5 |
| Leverage & cash | ||||||||
| Debt to equity | 0.26 | 0.27 | 0.24 | 0.22 | 0.18 | 0.03 | 0.03 | 0.00 |
| Cash flow ÷ profit | — | — | 0.75 | 0.61 | 1.22 | -0.10 | 0.37 | — |
| Current ratio | 2.25 | 1.85 | 1.96 | 1.28 | 1.20 | 1.09 | 1.47 | 1.66 |